Baird Financial Group Inc. increased its stake in Haleon PLC Sponsored ADR (NYSE:HLN - Free Report) by 264.6% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 69,350 shares of the company's stock after purchasing an additional 50,328 shares during the period. Baird Financial Group Inc.'s holdings in Haleon were worth $714,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC boosted its stake in Haleon by 6.1% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,223 shares of the company's stock worth $306,000 after purchasing an additional 1,749 shares in the last quarter. Oppenheimer & Co. Inc. lifted its stake in Haleon by 11.2% during the 1st quarter. Oppenheimer & Co. Inc. now owns 25,362 shares of the company's stock valued at $261,000 after acquiring an additional 2,564 shares during the period. Concurrent Investment Advisors LLC lifted its stake in Haleon by 32.9% during the 1st quarter. Concurrent Investment Advisors LLC now owns 16,363 shares of the company's stock valued at $168,000 after acquiring an additional 4,055 shares during the period. Mather Group LLC. lifted its stake in Haleon by 60.7% during the 1st quarter. Mather Group LLC. now owns 9,036 shares of the company's stock valued at $93,000 after acquiring an additional 3,413 shares during the period. Finally, Farther Finance Advisors LLC lifted its stake in Haleon by 8.8% during the 1st quarter. Farther Finance Advisors LLC now owns 12,861 shares of the company's stock valued at $131,000 after acquiring an additional 1,041 shares during the period. 6.67% of the stock is currently owned by institutional investors and hedge funds.
Haleon Stock Performance
Shares of HLN traded down $0.13 during trading hours on Monday, hitting $9.69. The stock had a trading volume of 7,189,494 shares, compared to its average volume of 7,791,135. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.63 and a current ratio of 0.87. The firm has a 50-day moving average price of $9.72 and a 200 day moving average price of $10.20. Haleon PLC Sponsored ADR has a fifty-two week low of $8.86 and a fifty-two week high of $11.42. The firm has a market capitalization of $43.35 billion, a price-to-earnings ratio of 24.83, a PEG ratio of 2.90 and a beta of 0.23.
Haleon Increases Dividend
The company also recently announced a semi-annual dividend, which will be paid on Thursday, September 18th. Investors of record on Friday, August 15th will be paid a $0.0555 dividend. The ex-dividend date is Friday, August 15th. This represents a dividend yield of 190.0%. This is an increase from Haleon's previous semi-annual dividend of $0.05. Haleon's dividend payout ratio (DPR) is presently 28.21%.
Wall Street Analyst Weigh In
Several brokerages have commented on HLN. BNP Paribas Exane upgraded shares of Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 price objective for the company in a research note on Tuesday, May 27th. BNP Paribas upgraded shares of Haleon to a "strong-buy" rating in a research note on Tuesday, May 27th. Wall Street Zen cut shares of Haleon from a "buy" rating to a "hold" rating in a research note on Saturday, July 12th. Finally, The Goldman Sachs Group upgraded shares of Haleon from a "neutral" rating to a "buy" rating in a research note on Wednesday, September 10th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, Haleon currently has a consensus rating of "Moderate Buy" and an average price target of $12.33.
Check Out Our Latest Analysis on HLN
Haleon Company Profile
(
Free Report)
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
Featured Stories
Before you consider Haleon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haleon wasn't on the list.
While Haleon currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
